Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 13/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12012163 | 0.82 | RET (0.34) | ALDH1A1POLBDHODH | |
| SCHEMBL12013030 | 0.78 | POLB (0.37) | ALDH1A1POLB | |
| SCHEMBL9377617 | 0.75 | GRM5 (0.33) | — | |
| SCHEMBL12012169 | 0.74 | POLB (0.35) | ALDH1A1POLBDHODH | |
| SCHEMBL12013041 | 0.71 | BRD4 (0.38) | ALDH1A1POLBL3MBTL1 | |
| SCHEMBL3532688 | 0.67 | GAA (0.33) | ALDH1A1POLB | |
| SCHEMBL11914660 | 0.65 | ALDH1A1 (0.31) | ALDH1A1POLB | |
| SCHEMBL10282161 | 0.65 | POLB (0.47) | ALDH1A1POLB | |
| SCHEMBL30924557 | 0.65 | ALDH1A1 (0.40) | ALDH1A1DHODH | |
| SCHEMBL3783636 | 0.64 | POLB (0.35) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009101917-A1 | BICYCLOAMINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | ALDH1A1 1852/4885POLB 3367/4885DHODH 3831/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | ALDH1A1 1852/4885POLB 3367/4885DHODH 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.